Cardinal Health’s 2026 Advanced Therapies Report gathers insights from over 160 physicians and administrators to assess the transition of gene, cell and tissue therapies from inpatient to community settings. It highlights the growing provider momentum to enhance patient access, flexibility and experience by administering treatments closer to home.

The survey reveals that 97% of health systems endorse partnerships between hospitals and community practices as essential for safe, high-quality advanced therapy delivery. Additionally, 96% of respondents agree that expanding into outpatient settings will increase capacity for innovative treatments.

There are currently 61 advanced therapies approved in the U.S., predominantly in oncology, with expectations to nearly triple that number by 2030. The report also notes accelerating innovation in neurology, rheumatology, ophthalmology and cardiology, underscoring the industry’s rapid expansion.

Establishing community-based advanced therapy programs demands extensive preparation: 48% of community practices report spending one to two years on clinical and operational planning. Key investments include technology for care coordination, specialized staffing and streamlined referral workflows to ensure program sustainability.